SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Rosenquist Richard)
 

Sökning: WFRF:(Rosenquist Richard) > (2020-2024) > Tumor-activated lym...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007004naa a2200685 4500
001oai:DiVA.org:uu-509146
003SwePub
008230816s2023 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:153311743
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5091462 URI
0247 a https://doi.org/10.1172/JCI1660702 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1533117432 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Apollonio, Benedettau Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, London, England.;Ist Tumori Giovanni Paolo II, Dept Rare Tumors & Melanoma, Lab Tumor Immunol & Immunotherapy, Viale O Flacco 65, I-70124 Bari, Italy.4 aut
2451 0a Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma
264 1b American Society for Clinical Investigation,c 2023
338 a electronic2 rdacarrier
520 a Recent transcriptomic-based analysis of diffuse large B cell lymphoma (DLBCL) has highlighted the clinical relevance of LN fibroblast and tumor-infiltrating lymphocyte (TIL) signatures within the tumor microenvironment (TME). However, the immunomodulatory role of fibroblasts in lymphoma remains unclear. Here, by studying human and mouse DLBCL-LNs, we identified the presence of an aberrantly remodeled fibroblastic reticular cell (FRC) network expressing elevated fibroblast activated protein (FAP). RNA-Seq analyses revealed that exposure to DLBCL reprogrammed key immunoregulatory pathways in FRCs, including a switch from homeostatic to inflammatory chemokine expression and elevated antigen-presentation molecules. Functional assays showed that DLBCL-activated FRCs (DLBCL-FRCs) hindered optimal TIL and chimeric antigen receptor (CAR) T cell migration. Moreover, DLBCL-FRCs inhibited CD'+ TIL cytotoxicity in an antigen-specific manner. Notably, the interrogation of patient LNs with imaging mass cytometry identified distinct environments differing in their CD'+ TIL-FRC composition and spatial organization that associated with survival outcomes. We further demonstrated the potential to target inhibitory FRCs to rejuvenate interacting TILs. Cotreating organotypic cultures with FAP-targeted immunostimulatory drugs and a bispecific antibody (glofitamab) augmented antilymphoma TIL cytotoxicity. Our study reveals an immunosuppressive role of FRCs in DLBCL, with implications for immune evasion, disease pathogenesis, and optimizing immunotherapy for patients.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Spada, Filomenau Guys & St Thomass NHS Fdn Trust, BRC Adv Cytometry Platform, London, England.4 aut
7001 a Petrov, Nedyalkou Guys & St Thomass NHS Fdn Trust, BRC Adv Cytometry Platform, London, England.4 aut
7001 a Cozzetto, Domenicou Guys & St Thomass NHS Fdn Trust, BRC Translat Bioinformat, London, England.;Kings Coll London, London, England.;Imperial Coll London, Fac Med, Div Digest Dis, London, England.4 aut
7001 a Papazoglou, Despoinau Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, London, England.4 aut
7001 a Jarvis, Peteru Aristotle Univ Thessaloniki, Surg Dept 5, Thessaloniki, Greece.4 aut
7001 a Kannambath, Shichinau Kings Coll London, London, England.;Guys & St Thomass NHS Fdn Trust, BRC Genom Res Platform, London, England.4 aut
7001 a Terranova-Barberio, Manuelau Guys & St Thomass NHS Fdn Trust, BRC Adv Cytometry Platform, London, England.4 aut
7001 a Amini, Rose-Marieu Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)roseamin
7001 a Enblad, Gunillau Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)gunienbl
7001 a Graham, Charlotteu Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, London, England.4 aut
7001 a Benjamin, Reubenu Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, London, England.4 aut
7001 a Phillips, Elisabethu Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, London, England.4 aut
7001 a Ellis, Richardu Guys & St Thomass NHS Fdn Trust, BRC Adv Cytometry Platform, London, England.4 aut
7001 a Nuamah, Rosamond4 aut
7001 a Saqi, Mansooru Guys & St Thomass NHS Fdn Trust, BRC Translat Bioinformat, London, England.;Kings Coll London, London, England.4 aut
7001 a Calado, Dinis P.u Francis Crick Inst, Immun & Canc Lab, London, England.4 aut
7001 a Rosenquist, Richardu Karolinska Institutet4 aut
7001 a Sutton, Lesley A.u Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden.4 aut
7001 a Salisbury, Jonu Kings Coll Hosp NHS Fdn Trust, Dept Haematol, London, England.4 aut
7001 a Zacharioudakis, Georgiosu Aristotle Univ Thessaloniki, Surg Dept 5, Thessaloniki, Greece.4 aut
7001 a Vardi, Annau G Papanikolaou Hosp, Hematol Dept, Thessaloniki, Greece.;G Papanikolaou Hosp, HCT Unit, Thessaloniki, Greece.4 aut
7001 a Hagner, Patrick R.u Bristol Myers Squibb, Summit, NJ USA.4 aut
7001 a Gandhi, Anita K.u Bristol Myers Squibb, Summit, NJ USA.4 aut
7001 a Bacac, Marinau Roche Innovat Ctr Zurich, Schlieren, Switzerland.4 aut
7001 a Claus, Christinau Roche Innovat Ctr Zurich, Schlieren, Switzerland.4 aut
7001 a Umana, Pablou Roche Innovat Ctr Zurich, Schlieren, Switzerland.4 aut
7001 a Jarrett, Ruth F.u Univ Glasgow, MRC, Ctr Virus Res, Glasgow, Scotland.4 aut
7001 a Klein, Christianu Roche Innovat Ctr Zurich, Schlieren, Switzerland.4 aut
7001 a Deutsch, Alexanderu Med Univ Graz, Div Hematol, Graz, Austria.4 aut
7001 a Ramsay, Alan G.u Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, London, England.;Guys Canc Ctr, Lymphoma Immunol, Innovat Hub, London SE1 9RT, England.4 aut
7102 a Kings Coll London, Fac Life Sci & Med, Sch Canc & Pharmaceut Sci, London, England.;Ist Tumori Giovanni Paolo II, Dept Rare Tumors & Melanoma, Lab Tumor Immunol & Immunotherapy, Viale O Flacco 65, I-70124 Bari, Italy.b Guys & St Thomass NHS Fdn Trust, BRC Adv Cytometry Platform, London, England.4 org
7730 t Journal of Clinical Investigationd : American Society for Clinical Investigationg 133:13q 133:13x 0021-9738x 1558-8238
8564 u https://uu.diva-portal.org/smash/get/diva2:1788598/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-509146
8564 8u https://doi.org/10.1172/JCI166070
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:153311743

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy